Iron metabolism disorders in patients with hepatitis B-related liver diseases

Table 1 Demographic and clinical characteristics of the participants in the study groups

	HC	CHB	LC	HCC	P-value
Characteristic	(n = 78)	(n = 78)	(n = 85)	(n = 77)
Gender (M/F)	48/30	53/25	54/31	62/15	0.05
Age (yr)	44 (25-67)	46 (30-61)	49 (27-65)	49 (22-57)	0.137
ALT (U/L)	14.95 (4.4-564)	122.9 (7-1906)	64 (8-855)	41 (15-450.2)	< 0.01
AST (U/L)	21.55 (11.0-38.5)	75.5 (14-1499)	56 (16-845)	56 (19-634)	< 0.01
ALB (g/L)	48.22 ± 2.51	38.01 ± 5.82	32.10 ± 6.87	34.56 ± 6.56	< 0.01
HGB (g/L)	147.79 ± 13.80	145.41 ± 17.74	126.33 ± 22.70	133.58 ± 22.5	< 0.01
PLT (× 109/L)	217 (117-328)	152.5 (55-298)	79 (28-303)	124 (17-515)	< 0.01
APRI	0.24 (0.1-0.5)	1.25 (0.16-68.14)	2.05 (0.24-42.25)	1.49 (0.24-9.43)	< 0.01
HBV-DNA (Log10)	0 (0-0)	6.64 (1.3-8.91)	4.96 (1.7-8.35)	4.61 (1.7-7.88)	< 0.01

M: Male; F: Female; HC: Healthy controls; CHB: Chronic hepatitis B; LC: Liver cirrhosis; HCC: Hepatocellular carcinoma; ALT: Alanine aminotransferase; AST: Aspartate transaminase; ALB: Albumin; HGB: Hemoglobin; PLT: Platelets; APRI: AST to platelet ratio index; HBV: Hepatitis B virus.